RALEIGH, NC – BioDelivery Sciences International Inc. (Nasdaq:BDSI), a specialty pharmaceutical company has entered into a definitive securities purchase agreement with a group of select institutional investors to purchase $10 million of its securities in a registered direct offering.
The company uses its proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.
BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.
Southeast Venture Conference, February 29 – March 1, 2012 at the Ritz Carlton in Tysons Corner, VA – Where Smart Money Meets Smart People.
www.seventure.org
© 2010, TechJournal South. All rights reserved.
Tags: Biodelivery Sciences, Biotech, financing, NC
